CURE vs XLVX: Leverage, Returns & Decay
Over three months to Nov 13, 2026, against its daily multiple, compounded, CURE finished 3.3 points short and XLVX 2.9 points short.
- Return gap
- +14.0 pts3 months to Nov 13, 2026: CURE ahead, total return
- Fee gap
- 0.49 ptsA year: CURE 0.94%, XLVX 0.45%, per filings dated Mar 3, 2026 and Jun 11, 2026
- Overlap
- –No book read for both funds
- Net flow
- –Needs daily flows for both funds
Compare two other funds
Growth of 100
Drawn from the numbers on this page. Growth of 100, both funds, distributions reinvested
CURE +38.2%, XLVX +24.2%: CURE +14.0 pts ahead, 3 months, Aug 14, 2026 to Nov 13, 2026.
ShareUse this comparison
No client brief for this pair: ETFIQ prints no one-year total return for XLVX.
Fees over time
Hypothetical. $10,000 in CURE for 10 years at 0.94% a year costs about $1,526 in fees and lost growth; XLVX at 0.45% would cost $746. Assumes 6% a year before fees, a sample rate, not a forecast.
How each fund moved
CURE returned +38.2% while 3 times XLV's move would have been +39.9%. Data from Aug 14, 2026 to Nov 13, 2026.
Data from Aug 14, 2026 to Nov 13, 2026.XLVX returned +24.2% while 2 times XLV's move would have been +26.6%. Data from Aug 14, 2026 to Nov 13, 2026.
XLVX returned +24.2% while 2 times XLV's move would have been +26.6%. Data from Aug 14, 2026 to Nov 13, 2026.IQ Leverage Score
How closely it delivered its daily multiple over 3 months, ranked against 31 leveraged ETFs at 3x, over three months and 498 leveraged ETFs at 2x, over three months. 100 is best.
XLVX scores higher · Did it keep up with its own daily multiple, compounded day by day, over three months?
CURE among the 31 leveraged ETFs at 3x, over three months
XLVX among the 498 leveraged ETFs at 2x, over three months
A percentile among the 31 leveraged ETFs at 3x, over three months. XLVX is a percentile among the 498 leveraged ETFs at 2x, over three months, a different set, so the two marks are not on one scale. Three months only, against the fund's own daily multiple; a different quarter can rank it very differently.
Key numbers
XLVX costs 0.49 points a year less; CURE is far larger, $209m against $1.8m.
Pair scorecard
Open the table
Points (pts) are percentage points.
| Total return, 1 year | +65.7% | not published |
|---|---|---|
| What its daily multiple gave, 3 months | 41.5% | 27.1% |
| What the underlying did, 3 months | XLV 13.3% | XLV 13.3% |
| What the underlying did, 3 months | XLV 13.3% | XLV 13.3% |
| What it tracks | Healthcare | U.S. Healthcare |
| Expense ratio | 0.94% | 0.45% |
| Net assets, as of Nov 12, 2026 | $209m | $1.8m |
| Holdings in common | not published |
The numbers behind it
Net assets: $209m on Nov 12, 2026 for Direxion Daily Healthcare Bull 3X ETF, and $1.8m on Nov 13, 2026 for Corgi U.S. Healthcare 2x Daily ETF.
Side by side
Open the table
| Fund | Direxion Daily Healthcare Bull 3X ETF · Aims to return three times the daily move of health care (XLV) | Corgi U.S. Healthcare 2x Daily ETF · Aims to return twice the daily move of health care (XLV) |
| Issuer | Direxion | Corgi |
| Sets out to return | +3x | +2x |
| Underlying asset | XLV | XLV |
| Segment | sector | sector |
| Fund returned, 3 months | +38.2% | +24.2% |
| Underlying returned, over that window | +13.3% | +13.3% |
| What the stated multiple implies, over that window | +39.9% | +26.6% |
| Difference from stated, over that window | −1.7 pts | −2.4 pts |
| Fund returned, 1 year | +65.7% | +57.1% (since launch, Jun 3, 2026) |
| Difference from stated, over that window | −11.4 pts | −0.9 pts (since launch, Jun 3, 2026) |
| Underlying volatility | 19% | 19% |
| Difference over the days both have traded | no shared window | −2.4 pts |
| Expense ratio | 0.94% | 0.45% |
| First traded | Jun 15, 2011 | Jun 3, 2026 |
| Net assets, CURE as of Nov 12, 2026 and XLVX as of Nov 13, 2026 | $209m | $1.8m |
As of Nov 13, 2026. Source: ETFIQ.
Window by window
Open the full table
| 1 month | +25.9% | +16.3% | +25.8% | +17.2% | +0.1 pts | −0.9 pts |
|---|---|---|---|---|---|---|
| 3 months | +38.2% | +24.2% | +39.9% | +26.6% | −1.7 pts | −2.4 pts |
| 6 months | +104.8% | – | +93.6% | – | +11.2 pts | – |
| 1 year | +65.7% | – | +77.1% | – | −11.4 pts | – |
| 3 years | +117.4% | – | +165.6% | – | −48.2 pts | – |
| Since launch (Not the same days: CURE Jun 2011 · XLVX Jun 2026) | +3,894.1% | +57.1% | not meaningful | +58.0% | not meaningful | −0.9 pts |
– means no data for this window.
From Jun 2026 to Nov 2026, CURE returned more: +71.0% to +44.1%. XLVX fell less at its worst: −10.9% to −15.8%.
Full scorecard
Open the full table
| Total return | +71.0% | +44.1% | CURE | Price change plus distributions, reinvested. |
| Price return | +70.0% | +44.1% | CURE | Price change alone, distributions left out. |
| Max drawdown | −15.8% | −10.9% | XLVX | Deepest fall from a high to the low after it. |
More
Computed by ETFIQ from Tiingo daily prices and ETFIQ's distribution records, 22 weekly returns. Cash rate: the 13-week Treasury bill.
About CURE
Over the three months to Nov 13, 2026, CURE returned 38.2%, against 41.5% for three times XLV's daily moves. Read the multiple against the whole window instead and 3 times XLV's 13.3% implies +39.9%, which makes CURE look 1.7 points short. That is not the fund's objective, which is daily. Of that 1.7, daily compounding is +1.6 points, which any 3 times fund would show over the same path, and the fund itself is −3.3 points against 3 times each day's move, compounded. CURE aims to return +3 times XLV's move each day, then resets. Over one day it does that. Over longer periods the daily results compound, so the total is not +3 times the period's move: it is lower after a fall and recovery, and can be higher in a steady run. XLV moved at 19% annualized over that window. The more it moves, the further the two numbers separate.
About XLVX
Over the three months to Nov 13, 2026, XLVX returned 24.2%, against 27.1% for twice XLV's daily moves. Read the multiple against the whole window instead and 2 times XLV's 13.3% implies +26.6%, which makes XLVX look 2.4 points short. Of that 2.4, daily compounding is +0.5 points, which any 2 times fund would show over the same path, and the fund itself is −2.9 points against 2 times each day's move, compounded. XLVX aims to return +2 times XLV's move each day, then resets. Over longer periods the daily results compound, so the total is not +2 times the period's move: it is lower after a fall and recovery, and can be higher in a steady run.
Questions people ask
Which came closer to its daily multiple, CURE or XLVX?
Over the window to Nov 13, 2026, CURE finished 1.7 points from what its multiple implies and XLVX finished 2.4 points from its own, so CURE came closer. Neither number predicts the next window: it depends on how much the underlying moves about.
Are CURE and XLVX levered on the same thing?
Yes. Both are levered on health care, CURE at +3 times and XLVX at +2 times the daily move.
Which one decays faster, CURE or XLVX?
Decay follows how much the underlying moves about. Over this window CURE’s moved at 19% annualized and XLVX’s at 19%, so CURE has the rougher ride and, at the same multiple, loses more to compounding.
Can I hold CURE or XLVX for a year?
Both reset every day, so the multiple in the name applies to a single day, and daily results compound. Over a year the total is not the multiple times the year’s move; after a fall and recovery it is lower.
Other comparisons
Sources
More
Links are sources, not endorsements. A comparison is not a recommendation.
Copy and cite
Cite this pageCitation, APA and Markdown
ETFIQ, CURE against XLVX, data as of Nov 13, 2026. https://etfiq.com/compare/leverage/cure-vs-xlvx
ETFIQ. (Nov 13, 2026). CURE against XLVX. Retrieved from https://etfiq.com/compare/leverage/cure-vs-xlvx
[CURE against XLVX (ETFIQ, Nov 13, 2026)](https://etfiq.com/compare/leverage/cure-vs-xlvx)
Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.